These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30780831)

  • 1. Clinical overview of saxagliptin for Type 2 diabetes management.
    Rosenstock J
    Expert Rev Endocrinol Metab; 2010 Nov; 5(6):809-823. PubMed ID: 30780831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.
    Kulasa K; Edelman S
    Core Evid; 2010 Oct; 5():23-37. PubMed ID: 21042540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saxagliptin for type 2 diabetes.
    Chacra AR
    Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin.
    Dhillon S; Weber J
    Drugs; 2009 Oct; 69(15):2103-14. PubMed ID: 19791828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
    Hollander PA; Kushner P
    Postgrad Med; 2010 May; 122(3):71-80. PubMed ID: 20463416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.
    Sharma MD
    Ther Clin Risk Manag; 2010 May; 6():233-7. PubMed ID: 20526441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
    Konya H; Yano Y; Matsutani S; Tsunoda T; Ikawa T; Kusunoki Y; Matsuo T; Miuchi M; Katsuno T; Hamaguchi T; Miyagawa J; Namba M
    Ther Clin Risk Manag; 2014; 10():547-58. PubMed ID: 25050065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
    Gallwitz B
    Diabetes Metab Syndr Obes; 2010 May; 3():117-24. PubMed ID: 21437082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitus.
    Vilsbøll T
    Expert Rev Endocrinol Metab; 2008 Jan; 3(1):13-19. PubMed ID: 30743780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saxagliptin plus metformin combination therapy.
    Scheen AJ
    Expert Rev Endocrinol Metab; 2012 Mar; 7(2):151-164. PubMed ID: 30764006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea.
    Aronson R
    Expert Opin Pharmacother; 2012 Jul; 13(10):1535-9. PubMed ID: 22587735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2010 Sep; 65(9):527-32. PubMed ID: 21086586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
    Lam S; Saad M
    Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.
    Gerich J
    Int J Gen Med; 2013 Dec; 6():877-95. PubMed ID: 24403842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.